NASDAQ:GANX Gain Therapeutics (GANX) Stock Price, News & Analysis → [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad) Free GANX Stock Alerts $3.17 -0.01 (-0.31%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$3.12▼$3.4350-Day Range$3.09▼$4.8252-Week Range$2.00▼$5.65Volume53,675 shsAverage Volume155,439 shsMarket Capitalization$51.42 millionP/E RatioN/ADividend YieldN/APrice Target$8.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Gain Therapeutics alerts: Email Address Gain Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside162.9% Upside$8.33 Price TargetShort InterestHealthy1.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.95Based on 2 Articles This WeekInsider TradingAcquiring Shares$115,800 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.17) to ($1.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.41 out of 5 starsMedical Sector282nd out of 910 stocksPharmaceutical Preparations Industry120th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingGain Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGain Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.02% of the float of Gain Therapeutics has been sold short.Short Interest Ratio / Days to CoverGain Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gain Therapeutics has recently decreased by 11.87%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGain Therapeutics does not currently pay a dividend.Dividend GrowthGain Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GANX. Previous Next 3.3 News and Social Media Coverage News SentimentGain Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Gain Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for GANX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gain Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $115,800.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.00% of the stock of Gain Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.97% of the stock of Gain Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gain Therapeutics are expected to grow in the coming year, from ($1.17) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gain Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gain Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGain Therapeutics has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Gain Therapeutics Stock (NASDAQ:GANX)Gain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Read More GANX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GANX Stock News HeadlinesApril 2, 2024 | insidertrades.comGain Therapeutics, Inc. (NASDAQ:GANX) Director Buys $115,800.00 in StockApril 20, 2024 | investing.comGain Therapeutics Inc (GANX)April 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 17, 2024 | finance.yahoo.comHere's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom FisherApril 8, 2024 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial OfficerApril 8, 2024 | markets.businessinsider.comGain Therapeutics Appoints Gene Mack As CFO; Stock FallsApril 8, 2024 | globenewswire.comGain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial OfficerApril 4, 2024 | msn.comFormer Gildan CEO considered acquisition of Hanesbrands - BloombergApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 1, 2024 | finance.yahoo.comDirector Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)April 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gain Therapeutics on Promising Parkinson’s Treatment and Solid Financial OutlookApril 1, 2024 | finance.yahoo.comGain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical OfficerMarch 28, 2024 | markets.businessinsider.comOptimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson’s Drug Candidate GT-02287March 27, 2024 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate UpdateMarch 26, 2024 | globenewswire.comGain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate UpdateMarch 15, 2024 | globenewswire.comGain Therapeutics to Present at Public Ventures Discovery DayMarch 5, 2024 | msn.comEXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's DiseaseMarch 5, 2024 | finance.yahoo.comGain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s DiseaseFebruary 27, 2024 | finance.yahoo.comGain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseFebruary 27, 2024 | globenewswire.comGain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's DiseaseFebruary 23, 2024 | benzinga.comGain Therapeutics Stock (NASDAQ:GANX), Short Interest ReportFebruary 17, 2024 | finance.yahoo.comGANX Mar 2024 7.500 callFebruary 16, 2024 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst InsightFebruary 14, 2024 | finance.yahoo.comGain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst InsightFebruary 14, 2024 | globenewswire.comGain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst InsightFebruary 7, 2024 | markets.businessinsider.comBuy Rating for Gain Therapeutics Backed by Strong Preclinical Data and Promising Parkinson’s Candidate GT-02287February 6, 2024 | marketwatch.comAmgen 4Q Revenue Surges as Acquisition Boosts ResultsSee More Headlines Receive GANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today4/23/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GANX CUSIPN/A CIK1819411 Webwww.gaintherapeutics.com Phone301-500-1556FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$8.33 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+162.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,270,000.00 Net MarginsN/A Pretax Margin-40,210.22% Return on Equity-193.03% Return on Assets-123.21% Debt Debt-to-Equity Ratio0.04 Current Ratio3.59 Quick Ratio3.59 Sales & Book Value Annual Sales$55,180.00 Price / Sales931.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book3.27Miscellaneous Outstanding Shares16,220,000Free Float14,436,000Market Cap$51.42 million OptionableOptionable Beta0.43 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Khalid Islam Ph.D. (Age 69)Founder & Chairman Comp: $75kMr. Matthias Alder LIC. IUR. (Age 59)LL.M., President, CEO & Director Comp: $593kMr. Gianluca Fuggetta (Age 35)VP of Finance, Senior Dir. of Corp. Reporting, Principal Acc. Off., & Principal Financial Off. Dr. Manolo Bellotto Ph.D. (Age 53)GM & Chief Strategy Officer Comp: $251.99kDr. Joanne Taylor Ph.D.Senior Vice President of ResearchDr. Terenzio Ignoni Pharm.D.Senior Vice President of Technical OperationsMore ExecutivesKey CompetitorsSCYNEXISNASDAQ:SCYXJaguar HealthNASDAQ:JAGXDaré BioscienceNASDAQ:DAREImmuneeringNASDAQ:IMRXApollomicsNASDAQ:APLMView All CompetitorsInsidersJeffrey Scott RileyBought 30,000 shares on 3/28/2024Total: $115,800.00 ($3.86/share)Matthias AlderSold 206 sharesTotal: $506.76 ($2.46/share)View All Insider Transactions GANX Stock Analysis - Frequently Asked Questions Should I buy or sell Gain Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gain Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GANX shares. View GANX analyst ratings or view top-rated stocks. What is Gain Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 12-month price objectives for Gain Therapeutics' shares. Their GANX share price targets range from $6.00 to $10.00. On average, they anticipate the company's stock price to reach $8.33 in the next year. This suggests a possible upside of 162.9% from the stock's current price. View analysts price targets for GANX or view top-rated stocks among Wall Street analysts. How have GANX shares performed in 2024? Gain Therapeutics' stock was trading at $3.27 on January 1st, 2024. Since then, GANX shares have decreased by 3.1% and is now trading at $3.17. View the best growth stocks for 2024 here. Are investors shorting Gain Therapeutics? Gain Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 138,100 shares, a decrease of 11.9% from the March 15th total of 156,700 shares. Based on an average daily volume of 161,800 shares, the short-interest ratio is presently 0.9 days. Approximately 1.0% of the company's stock are short sold. View Gain Therapeutics' Short Interest. When is Gain Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our GANX earnings forecast. How were Gain Therapeutics' earnings last quarter? Gain Therapeutics, Inc. (NASDAQ:GANX) announced its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.03. When did Gain Therapeutics IPO? Gain Therapeutics (GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager. How do I buy shares of Gain Therapeutics? Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GANX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
